Fri, Nov 28, 2014, 8:39 PM EST - U.S. Markets closed early today

Recent

% | $
Quotes you view appear here for quick access.

Emisphere Technologies, Inc. Message Board

  • SortNewest  |  Oldest  |  Most Replied Expand all replies
    • i love to hear you/mike talk that way.

      $1000 per sh is ~$18b market cap. while big, it needs somewhere around $1B in sales with a reasonably promising product line in trials to justify an 18:1 price to sales ratio. Bio/pharma P/S range between 8 and 40 with 20 about average.

      The question is, when will we have a billion in sales?

      The anticoagulant mkt is somewhere around $6B but includes all indications and drugs ie coumadin. if emis gets approval for all indications, has pills/liquids/tablets of ufh & lmwh, and a good partner, i believe we could see our billion in sales just from hep.

      but how long to do all the trials and get all the approvals? ... it feels like it could take a hundred years at this rate

    • Hey, even drug dealers use scales rather than this device - they are concerned their customer shoots them for undercharging...
      Seriously, FDA will never authorize the sale of insulin or any drug as powder for the patients to fill the dosage caps themselves. Besides obvious imprecise dose considerations, there are also issues of microbial contamination, moisture (this what the silica gel caps with the letters "do not eat" in your aspirin bottle are for), etc.

    • >>I've seen people breaking tablets of other medicines into partial doses, so maybe that will do the trick. Even taking multiple small tablets seems to me to be a better alternative than s.c. injection, if dose metering is the only issue. >>

      My diabetic sister in law's doctor already stated that breaking up pills would not be practical. But he is only one doctor. Perhaps providing smaller pills to aid in adjusting the dosage might help, who knows? Any doctors out there with an opinion on this?

    • Especially annoying when you see the closing price is below the closing bid, and after hours trades are higher than the close as well. Both of these happened yesterday and today.

    • It continues to amaze and disgust me how the MMs that control Emis trading can knock it down 50 cents every day in the last 10 minutes of trading.

      Had I not had a buy order sitting just below the closing price; they might have pushed it below 25; just like they did yesterday.

      No wonder I hate the Nasdaq. It gives certain firms a license to steal !

    • "At this point, the pill is not suited to juvenile-onset diabetics, because timing is very important. If such a patient swallows the pill, it's difficult to control the release
      of insulin over time that would balance the blood sugar level. Some mechanism that offers better control of insulin release could eventually make the oral insulin pill practical
      for type I diabetics," Kidron explained.

      My diabetic sister in law recently told me that her doctor would never prescribe oral insulin for type I diabetes because it can't be finely measured out like it can be when it is injected. This is important because the amount of insulin required varies according to the sugar level variance. Wonder if a liquid version of emis' oral insulin would overcome that problem. Still, it probably would not overcome the insulin release timing problem.

      • 3 Replies to goodbets
      • "Still, it probably would not overcome the insulin release timing problem."

        i must be missing something key. how does injected insulin obtain a timed release characteristic. i assume injected insulin is effective all at once.

        seems that a pill would not be that hard to obtain timed release characteristics by "wrapping" timed release coatings in sub-pills within the "main" pill. maybe Contac's don't really work this way, but the ads imply it.

      • >>>>>>At this point, the pill is not suited to juvenile-onset diabetics, because timing is very important. If such a patient swallows the pill, it's difficult to control the release
        of insulin over time that would balance the blood sugar level. Some mechanism that offers better control of insulin release could eventually make the oral insulin pill practical
        for type I diabetics," Kidron explained<<<<<<<

        Perhaps this is why EMIS is seeking to hire a scientist who specializes in controlled release of oral drugs (listed in the "Employment" section of thir website). More speculation>>>>I wonder if they plan to gear up part of the new lab in CT for this project. Then they could really devote the necessary resources to solving the above problem without upsetting whatever existing research is taking place in Tarrytown.

      • I question this statement regarding Type I diabetics.

        The current method of injecting insulin in the NON-enterohepatic soft tissues is likely the reason for the difficulty in managing the "brittle" diabetics.

        With oral delivery to the enter-hepatic curcuit, I would expect that the management of Type I "brittle" diabetics would be simplified and improved dramaticly.

    • Is this a confirmation that oral insulin phase I was successfuly concluded? It definitely looks like it to me.

      "Since our team is regarded as the best in the world involved in slowing the absorption of insulin, the New York company approached us and asked us to carry out clinical trials. The American insulin pill works differently from our own. In phase I trials on 12 healthy volunteers, we show that the active ingredient in the Emisphere pill can pass through the intestine and go on to the liver and the bloodstream within 20 or 30 minutes,"

      • 2 Replies to em_is_emis
      • >>>>>Is this a confirmation that oral insulin phase I was successfuly concluded? It definitely looks like it to me.<<<<<<

        It looks like this part of Phase I is complete. Remember we are also waiting to hear from the Dutch as well.

        The Israeli hospital mentions that diabetic patients will be tested next, which is a phase II item (phase I tests on healthy humans only).

 
EMIS
0.45+0.01(+2.27%)Nov 28 12:51 PMEST

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Energy XXI Ltd.
NasdaqGSFri, Nov 28, 2014 1:00 PM EST